Overview

Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide decitabine to patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) who have completed participation per protocol in the DACO-018 study.
Phase:
Phase 2
Details
Lead Sponsor:
Eisai Inc.
Treatments:
Azacitidine
Decitabine